Adamis Pharmaceuticals (United States)

Recent papers from Adamis Pharmaceuticals (United States)

1. EPHA2/CD44-directed trafficking enhances endosomal leakiness and antisense therapy deliveryThe Journal of Cell Biology · 2026
2. Surface Coverage Analysis Reveals Potential-Determining Heterolytic Reactions during Thermocatalytic Aerobic Glucose OxidationACS Catalysis · 2025
3. Towards Accurate Recognition of Historical Arabic Manuscripts: A Novel Dataset and a Generalizable PipelineACM Transactions on Asian and Low-Resource Language Information Processing · 2025
4. Brief Report: Higher Fentanyl Exposures Require Higher Doses of Naloxone for Successful Reversals in a Quantitative Systems Pharmacology ModelAddiction Research and Adolescent Behaviour · 2022
5. Brief Report: Higher Fentanyl Exposures Require Higher Doses of Naloxone for Successful Reversals in a Quantitative Systems Pharmacology Model2021
6. Meeting Report: Vaccine Stability Considerations to Enable Rapid Development and DeploymentAAPS Open · 2021
7. Higher naloxone dosing in a quantitative systems pharmacology model that predicts naloxone-fentanyl competition at the opioid mu receptor levelPLoS ONE · 2020
8. The Effects of Intramuscular Naloxone Dose on Mu Receptor Displacement of Carfentanil in Rhesus MonkeysMolecules · 2020
9. Higher doses of naloxone are needed in the synthetic opioid eraSubstance Abuse Treatment Prevention and Policy · 2019
10. Microsurgical Primary Prevention of Lymphatic Injuries following Breast Cancer TreatmentPlastic & Reconstructive Surgery · 2012
11. Propofol hemisuccinate suppression of experimental autoimmune encephalomyelitisAutoimmunity · 2007
12. Glucose Metabolism and Regulation: Beyond Insulin and GlucagonDiabetes Spectrum · 2004